Key facts
- Braveheart Bio is targeting a valuation of up to $1.2 billion in its U.S. IPO.
- Braveheart Bio aims to raise $318.8 million by offering 18.8 million shares.
- Braveheart Bio's shares are priced between $15 and $17 each.
- Reformation debuted on the NYSE at a valuation of $886.1 million.
- Reformation raised $210.9 million in its IPO.
- Reformation's shares opened flat on its NYSE debut.
- Jersey Mike's shares opened 8.7% below their IPO price.
- Jersey Mike's was valued at $6.7 billion in its NYSE debut.
- Jersey Mike's raised approximately $1 billion from its offering.
Several companies have recently entered the public markets through initial public offerings (IPOs), with mixed results. Braveheart Bio, a clinical-stage biopharmaceutical company, is aiming for a valuation of up to $1.2 billion in its U.S. IPO. The company plans to raise $318.8 million by offering 18.8 million shares with a price range of $15 to $17 per share.
In contrast, Reformation, a womenswear retailer backed by Permira, has already debuted on the New York Stock Exchange (NYSE). The company's IPO valued it at $886.1 million, and it successfully raised $210.9 million. Upon its market debut, Reformation's shares opened flat, indicating a stable initial reception.
Jersey Mike's, a well-known sandwich chain, experienced a less favorable market entry. Its shares opened on the NYSE at a price 8.7% below its IPO price. This debut valued the company at $6.7 billion, and it had raised approximately $1 billion from the offering prior to the share price drop.